We are currently implementing a project co-funded by the European Union entitled:

Short-chain fatty acids in the treatment of distal colon disorders

in
Operational Programme Smart Growth 2014–2020
Priority Axis: Support for R&D activities carried out by enterprises
Measure: R&D projects of enterprises
Sub-measure: Industrial research and development work carried out by enterprises
Application number: POIR.01.01.01-00-0354/20

Project value: 1.723.209,56 PLN

EU co-funding: 1.217.394,85 PLN
 

The aim of the project is to develop a ready-to-implement product containing short-chain fatty acids and soothing substances for use in diseases of the distal large intestine. The project involves developing the product formulation and production technology, as well as conducting a clinical study to confirm its effectiveness. The developed technology and clinical study results will be used to obtain certification for the new product and to prepare a patent application protecting the project outcomes. The main tasks include developing a formulation and production technology that ensure the delivery of active substances to the distal part of the large intestine. Oral preparations do not provide sufficient amounts of active substances to the final segment of the gastrointestinal tract. Therefore, preparations intended for the treatment of distal colon disorders require special solutions that allow short-chain fatty acids to be delivered to this specific area. Another key task will be conducting a clinical study in the target patient group to confirm the effectiveness of the new formulation. The target group includes patients with inflammatory diseases of the distal part of the colon: mucosal inflammation associated with inflammatory bowel diseases, and radiation-induced mucosal inflammation occurring during cancer treatment (prostate cancer, cervical cancer, endometrial cancer, ovarian cancer, and colorectal cancer). The target group also includes physicians treating the above-mentioned patients: gastroenterologists, proctologists, and general practitioners.
 

 

Completed Projects

An innovative form of butyric acid in the therapy of large intestine diseases

in
Programu Operacyjnego Inteligentny Rozwój 2014-2020
Priority Axis: Support for R&D activities carried out by enterprises
Measure: R&D projects of enterprises
Sub-measure: Industrial research and development work carried out by enterprises
Application number: POIR.01.01.01-00-0450/17

Project value: 543.17,71 PLN

EU co-funding: 390.481,07 PLN
 

The objective of the project is to develop a high-dose short-chain fatty acid formulation in an enteric-coated form administered once daily, intended for patients with functional and inflammatory bowel disorders. Short-chain fatty acids are components of natural animal and plant fats. They are also produced in the large intestine through the fermentation of fiber by the normal gut flora. Short-chain fatty acids are the primary nutritional source for the intestinal epithelium, particularly the colon. In many disease states, disturbances occur in the gut flora responsible for producing short-chain fatty acids. In other cases, the intestinal epithelium becomes damaged and the microbiota is altered. All these conditions lead to short-chain fatty acid deficiency, impaired nourishment of the intestinal epithelium and, as a result, disturbances in bowel function. Short-chain fatty acids are therefore used in the treatment of intestinal disorders, particularly functional and inflammatory diseases of the large intestine.